Evrofarma, an innovative Greek dairy company based in Thrace, northern Greece, has recently published the financial results for the period which ended June 30, 2020.
Namely, the company’s consolidated turnover amounted to €15,675 thousand compared to €17,466 thousand, showing a 10% decrease, while the corporate turnover amounted to €13,237 thousand compared to €15,075 thousand over the period covered, showing a 12% decrease. The decrease is mainly due to the effect of the restrictive measures taken by Greece to deal with the spread of the COVID-19 pandemic.
The gross consolidated margin stood at 20.42% against 21.84% and the corporate margin at 20.34% compared to 21.31% of the previous comparative period. In absolute terms, gross profit amounted to €3,201 thousand and €2,692 thousand compared to €3,814 thousand and €3,212 thousand for the consolidated and corporate level, respectively.
Earnings before interest, taxes, depreciation and depreciation (EBITDA) amounted to €1,454 thousand and €883 thousand for the Evrofarma group and the company respectively, compared to €2,191 thousand and €1,557 thousand for comparative information, reduced by 33.63% and 43.28% respectively.
Consolidated before tax profits amounted to €429 thousand against €537 thousand, reduced by 20.1% and corporate profits amounted to €25 thousand against €20 thousand.
Consolidated after tax profits amounted to €338 thousand against €221 thousand, showing an increase of 52.94%. Respectively, the company’s after tax profits amounted to €24 thousand against €167 thousand in losses for the comparative period.
READ MORE: Entrepreneurship
